JP6425661B2 - 透析組成物 - Google Patents
透析組成物 Download PDFInfo
- Publication number
- JP6425661B2 JP6425661B2 JP2015548467A JP2015548467A JP6425661B2 JP 6425661 B2 JP6425661 B2 JP 6425661B2 JP 2015548467 A JP2015548467 A JP 2015548467A JP 2015548467 A JP2015548467 A JP 2015548467A JP 6425661 B2 JP6425661 B2 JP 6425661B2
- Authority
- JP
- Japan
- Prior art keywords
- citrate
- acid
- dialysis
- citric acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 185
- 238000000502 dialysis Methods 0.000 title claims description 144
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 349
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 204
- 229940001468 citrate Drugs 0.000 claims description 201
- 239000002253 acid Substances 0.000 claims description 69
- 239000012141 concentrate Substances 0.000 claims description 39
- 239000000385 dialysis solution Substances 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 34
- 239000011734 sodium Substances 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 27
- 229910052708 sodium Inorganic materials 0.000 claims description 27
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 23
- 239000011575 calcium Substances 0.000 claims description 23
- 229910052791 calcium Inorganic materials 0.000 claims description 22
- 239000011777 magnesium Substances 0.000 claims description 21
- 239000003792 electrolyte Substances 0.000 claims description 20
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 19
- 229910052749 magnesium Inorganic materials 0.000 claims description 19
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 17
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 14
- 239000011591 potassium Substances 0.000 claims description 14
- 229910052700 potassium Inorganic materials 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000001509 sodium citrate Substances 0.000 claims description 14
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 13
- 235000019263 trisodium citrate Nutrition 0.000 claims description 13
- 229940038773 trisodium citrate Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000002526 disodium citrate Substances 0.000 claims description 7
- 235000019262 disodium citrate Nutrition 0.000 claims description 7
- 229940079896 disodium hydrogen citrate Drugs 0.000 claims description 7
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 7
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical group [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims description 7
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- RQALKBLYTUKBFV-UHFFFAOYSA-N 1,4-dioxa-7-thiaspiro[4.4]nonane Chemical compound O1CCOC11CSCC1 RQALKBLYTUKBFV-UHFFFAOYSA-N 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- UZLGHNUASUZUOR-UHFFFAOYSA-L dipotassium;3-carboxy-3-hydroxypentanedioate Chemical compound [K+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UZLGHNUASUZUOR-UHFFFAOYSA-L 0.000 claims description 4
- 239000002524 monosodium citrate Substances 0.000 claims description 4
- 235000018342 monosodium citrate Nutrition 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- UJASNKJSHULBIQ-UHFFFAOYSA-L disodium 3-carboxy-3-hydroxypentanedioate dihydrate Chemical compound O.O.[Na+].[Na+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UJASNKJSHULBIQ-UHFFFAOYSA-L 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 description 33
- 238000011282 treatment Methods 0.000 description 20
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 229960001031 glucose Drugs 0.000 description 17
- 229940091250 magnesium supplement Drugs 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 13
- 229960002897 heparin Drugs 0.000 description 13
- 229920000669 heparin Polymers 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 238000001631 haemodialysis Methods 0.000 description 12
- 230000000322 hemodialysis Effects 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000001802 infusion Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002699 waste material Substances 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002615 hemofiltration Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000014666 liquid concentrate Nutrition 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- -1 hydrogen citrate ions Chemical class 0.000 description 3
- 239000004337 magnesium citrate Substances 0.000 description 3
- 229960005336 magnesium citrate Drugs 0.000 description 3
- 235000002538 magnesium citrate Nutrition 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011635 calcium salts of citric acid Substances 0.000 description 2
- 235000019842 calcium salts of citric acid Nutrition 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000011637 magnesium salts of citric acid Substances 0.000 description 2
- 235000019848 magnesium salts of citric acid Nutrition 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-M 3-carboxy-2-(carboxymethyl)-2-hydroxypropanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-M 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
6mMまでのクエン酸塩、
約130〜150mMのナトリウム、好ましくは135〜145mMのナトリウム、またはより好ましくは140mMのナトリウム、
および20〜40mMの重炭酸塩、好ましくは25〜35mMの重炭酸塩、またはより好ましくは34mMの重炭酸塩、
0〜4mMのカリウム、
0〜1.5mMのマグネシウム、
0〜3mMのカルシウム、
0〜2g/Lのグルコース、および
電気的中性度によって決定される量の塩化物イオンを含み、
生理学的に許容されるpHが6.5〜8、より好ましくはpHが6.8〜7.5、たとえばpHが7.0〜7.4であってもよい
最終透析液となることが意図されている。
a)塩化ナトリウムを水に溶解する工程、
b)電解質(即ちカリウム、カルシウム、マグネシウム)をa)の混合物と混合することによって溶解する工程、
c)クエン酸を溶解する工程、
d)a、bおよびcの溶解したイオンを混合する工程、
e)クエン酸塩を溶解し、溶解したクエン酸塩をd)で得られた生成物に添加する工程、
を含む方法であって、工程a)、b)、c)、およびd)を逐次的に、任意の順序で、または2つ以上の工程を同時に実施する方法によって製造してもよい。
− クエン酸、塩化カルシウム、および塩化マグネシウムを添加する、および
− クエン酸塩を混合物に添加する。
例1〜6および8〜9による濃縮溶液についてpH測定を実施した。結果を表1に提示する。例1〜6および8〜9による溶液は、40℃の温度でガラスボトル中に保存した。4週間の期間の間、溶液のpH値を測定した。
以下に、本願の出願当初の請求項を実施の態様として付記する。
[1] クエン酸とクエン酸塩の混合物を含み、3.0未満のpHを有する酸濃縮透析組成物であって、クエン酸塩の全濃度が35mM〜450mMであり、クエン酸の量がクエン酸塩の全濃度の50%を超える酸濃縮透析組成物。
[2] クエン酸塩の全濃度が35mM〜270mMである、[1]に記載の酸濃縮透析組成物。
[3] 前記組成物がクエン酸とクエン酸塩の混合物を含み、クエン酸の量がクエン酸塩の全濃度の60%以上、好ましくはクエン酸塩の全濃度の70%を超え、より好ましくはクエン酸塩の全濃度の75%を超える、[1]に記載の酸濃縮透析組成物。
[4] 前記組成物がクエン酸とクエン酸塩の混合物を含み、クエン酸の量がクエン酸塩の全濃度の約70%〜約85%、好ましくはクエン酸塩の全濃度の約75%〜約85%である、[1]に記載の酸濃縮透析組成物。
[5] クエン酸対クエン酸塩の比が、1より大きい:1であり、好ましくはクエン酸対クエン酸塩の比が、2より大きい:1である、[1]〜[4]の何れか一項に記載の酸濃縮透析組成物。
[6] クエン酸対クエン酸塩の比が約1:1〜約10:1、好ましくは約2:1〜6:1、より好ましくは約3:1〜約6:1である、[1]〜[5]の何れか一項に記載の酸濃縮透析組成物。
[7] 前記透析組成物が2.8未満のpH、好ましくは2.6未満のpH、好ましくは2.5未満のpH、好ましくは0.5〜2.8のpH、好ましくは1.0〜2.6のpH、好ましくは1.5〜2.5のpHを有する、[1]〜[6]の何れか一項に記載の酸濃縮透析組成物。
[8] 前記クエン酸塩がクエン酸のナトリウム、カリウム、カルシウム、またはマグネシウム塩から選択される、[1]〜[7]の何れか一項に記載の酸濃縮透析組成物。
[9] 前記クエン酸塩がクエン酸二水素ナトリウム、クエン酸水素二ナトリウム、クエン酸三ナトリウム、クエン酸三ナトリウム二水和物、クエン酸二水素カリウム、クエン酸水素二カリウム、クエン酸カルシウム、およびクエン酸マグネシウムから選択され、好ましくは前記クエン酸塩がクエン酸三ナトリウム、クエン酸水素二ナトリウム、およびクエン酸二水素一ナトリウムから選択される、[1]〜[8]の何れか一項に記載の酸濃縮透析組成物。
[10] 前記酸濃縮透析組成物が希釈され、重炭酸塩含有溶液と混合されて、クエン酸塩の全濃度が1〜6mM、好ましくは1〜5mM、より好ましくは1.5〜4mMである透析溶液とされる、[1]〜[9]の何れか一項に記載の酸濃縮透析組成物。
[11] クエン酸およびクエン酸塩を含む[1]〜[10]の何れか一項に記載の酸濃縮透析組成物であって、
クエン酸塩の全濃度が35mM〜450mMであり、
クエン酸の量がクエン酸塩の全濃度の50%を超え、
クエン酸対クエン酸塩の比が、1より大きい:1であり、pHが3.0未満である酸濃縮透析組成物。
[12] [1]〜[11]の何れか一項に記載の酸濃縮透析組成物および生理学的に許容される電解質を含むクエン酸塩含有透析溶液。
[13] 前記透析溶液が1〜6mMのクエン酸塩の全濃度を有する、[12]に記載のクエン酸塩含有透析溶液。
[14] [13]に記載のクエン酸塩含有透析溶液であって、
透析液が、[1]〜[11]の何れか一項に記載の酸濃縮透析組成物を含み、
6mMまでのクエン酸塩、好ましくは1.5〜6.0mMのクエン酸塩、
約130〜150mMのナトリウム、好ましくは135〜145mMのナトリウム、またはより好ましくは140mMのナトリウム、および
20〜40mMの重炭酸塩、好ましくは25〜35mMの重炭酸塩、
0〜4mMのカリウム、
0〜1.5mMのマグネシウム、
0〜3mMのカルシウム、
0〜2g/Lのグルコース、および電気的中性度によって決定される塩化物イオンを含んでもよい、クエン酸塩含有透析溶液。
[15] [1]〜[11]の何れか一項に記載の酸濃縮透析組成物を製造するための方法であって、前記方法が、
a)塩化ナトリウムを水に溶解する工程、
b)電解質をa)の混合物と混合することによって溶解する工程、
c)クエン酸を溶解する工程、
d)a、bおよびcの塩化ナトリウム、電解質、およびクエン酸を混合する工程、
クエン酸塩をd)で得られた生成物に添加する工程を含み、
工程a)、b)、c)、およびd)を逐次的に、任意の順序で、または2つ以上の工程を同時に実施する方法。
[16] 透析液を調製するための[1]〜[11]の何れか一項に記載の酸濃縮物の使用。
[17] [1]〜[11]の何れか一項に記載の酸濃縮透析組成物を含むパッケージ。
Claims (12)
- 3500〜4622mMのナトリウム、
105〜180mMのカリウム、
56.3〜96.75mMのカルシウム、
17.5〜22.5mMのマグネシウム、
35〜45g/Lのグルコース、
電気的中性度によって決定される塩化物イオン、及び、
クエン酸とクエン酸塩の混合物を含み、2.2未満のpHを有する酸濃縮透析組成物であって、クエン酸塩の全濃度が35mM〜270mMであり、クエン酸の量がクエン酸塩の全濃度の75%を超える酸濃縮透析組成物。 - 前記組成物がクエン酸とクエン酸塩の混合物を含み、クエン酸の量がクエン酸塩の全濃度の約75%〜約85%である、請求項1に記載の酸濃縮透析組成物。
- クエン酸対クエン酸塩の比が約3:1〜約10:1、好ましくは約3:1〜約6:1である、請求項1〜2の何れか一項に記載の酸濃縮透析組成物。
- 前記クエン酸塩がクエン酸のナトリウム、カリウム、カルシウム、またはマグネシウム塩から選択される、請求項1〜3の何れか一項に記載の酸濃縮透析組成物。
- 前記クエン酸塩がクエン酸二水素ナトリウム、クエン酸水素二ナトリウム、クエン酸三ナトリウム、クエン酸三ナトリウム二水和物、クエン酸二水素カリウム、クエン酸水素二カリウム、クエン酸カルシウム、およびクエン酸マグネシウムから選択され、好ましくは前記クエン酸塩がクエン酸三ナトリウム、クエン酸水素二ナトリウム、およびクエン酸二水素一ナトリウムから選択される、請求項1〜4の何れか一項に記載の酸濃縮透析組成物。
- 前記酸濃縮透析組成物が希釈され、重炭酸塩含有溶液と混合されて、クエン酸塩の全濃度が1〜6mM、好ましくは1〜5mM、より好ましくは1.5〜4mMである透析溶液とされる、請求項1〜5の何れか一項に記載の酸濃縮透析組成物。
- 請求項1〜6の何れか一項に記載の酸濃縮透析組成物を、生理学的に許容される電解質とともに希釈することを含む、クエン酸塩含有透析溶液の製造方法。
- 前記透析溶液が1〜6mMのクエン酸塩の全濃度を有する、請求項7に記載のクエン酸塩含有透析溶液の製造方法。
- 前記透析溶液が、
6mMまでのクエン酸塩、好ましくは1.5〜6.0mMのクエン酸塩、
約130〜150mMのナトリウム、好ましくは135〜145mMのナトリウム、またはより好ましくは140mMのナトリウム、および
20〜40mMの重炭酸塩、好ましくは25〜35mMの重炭酸塩、
を含有する、請求項8に記載のクエン酸塩含有透析溶液の製造方法。 - 請求項1〜6の何れか一項に記載の酸濃縮透析組成物を製造するための方法であって、前記方法が、
a)塩化ナトリウムを水に溶解する工程、
b)電解質をa)の混合物と混合することによって溶解する工程、
c)クエン酸を溶解する工程、
d)a、bおよびcの塩化ナトリウム、電解質、およびクエン酸を混合する工程、
クエン酸塩をd)で得られた生成物に添加する工程を含み、
工程a)、b)、c)、およびd)を逐次的に、任意の順序で、または2つ以上の工程を同時に実施する方法。 - 透析液を調製するための請求項1〜6の何れか一項に記載の酸濃縮物の使用。
- 請求項1〜6の何れか一項に記載の酸濃縮透析組成物を含むパッケージ。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261738572P | 2012-12-18 | 2012-12-18 | |
US61/738,572 | 2012-12-18 | ||
SE1251447 | 2012-12-18 | ||
SE1251447-7 | 2012-12-18 | ||
PCT/EP2013/077019 WO2014095953A1 (en) | 2012-12-18 | 2013-12-18 | Dialysis composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016503768A JP2016503768A (ja) | 2016-02-08 |
JP6425661B2 true JP6425661B2 (ja) | 2018-11-21 |
Family
ID=50977627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015548467A Active JP6425661B2 (ja) | 2012-12-18 | 2013-12-18 | 透析組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9925155B2 (ja) |
EP (1) | EP2934483B1 (ja) |
JP (1) | JP6425661B2 (ja) |
KR (1) | KR102252944B1 (ja) |
CN (2) | CN104349770A (ja) |
AU (1) | AU2013201546B2 (ja) |
CA (1) | CA2893478C (ja) |
WO (1) | WO2014095953A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2826476B1 (en) * | 2013-07-16 | 2021-03-03 | G.M.T. de Jong B.V. | Calcium-free dialysis fluid |
PL3277339T3 (pl) * | 2015-03-31 | 2020-09-07 | Gambro Lundia Ab | Opakowanie dla kwaśnego koncentratu płynu dializacyjnego zawierającego cytrynian i glukozę |
IL299326A (en) * | 2015-08-18 | 2023-02-01 | Astellas Inst For Regenerative Medicine | Clinical formulations |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3560380A (en) | 1968-10-28 | 1971-02-02 | Mallinckrodt Chemical Works | Dry concentrates for preparing hemodialysis solutions |
US4756838A (en) | 1980-02-21 | 1988-07-12 | Veltman Preston Leonard | Preparation of dry dialysate products |
CA1241886A (en) | 1983-04-13 | 1988-09-13 | Peter W. Field | Enema bag |
AU627309B2 (en) | 1989-05-26 | 1992-08-20 | Terumo Kabushiki Kaisha | Preparation for blood dialysis and method for production thereof |
US5071558A (en) | 1989-08-11 | 1991-12-10 | Nikkiso Co., Ltd. | Sodium bicarbonate dialysate |
EP0567452B1 (en) | 1990-12-18 | 1996-05-15 | The Board Of Regents Of The University Of Washington | Dialysate production system with dialysate pellets |
JPH04257522A (ja) | 1991-02-07 | 1992-09-11 | Nikkiso Co Ltd | 重曹透析用剤 |
JP2769592B2 (ja) | 1992-12-14 | 1998-06-25 | 富田製薬株式会社 | 重炭酸透析用人工腎臓灌流用剤の製造方法及び人工腎臓灌流用剤 |
JP3619921B2 (ja) * | 1996-09-13 | 2005-02-16 | 富田製薬株式会社 | 重炭酸固形透析用剤 |
FR2766797B1 (fr) | 1997-07-30 | 1999-09-17 | Smad | Conditionnement pour au moins une matiere solide, notamment sous forme granuleuse ou pulverulente |
US6610206B1 (en) | 1998-10-20 | 2003-08-26 | Advanced Renal Technologies | Buffered compositions for dialysis |
US7670491B2 (en) | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
US6274103B1 (en) | 1999-03-26 | 2001-08-14 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
SE9901165D0 (sv) | 1999-03-30 | 1999-03-30 | Gambro Lundia Ab | Method, apparatus and components of dialysis systems |
DE60009791T2 (de) | 1999-06-07 | 2004-08-19 | Nipro Corp. | Feste pharmazeutische Zubereitung für die Dialyse sowie Verfahren zu deren Herstellung |
ATE422915T1 (de) | 1999-09-22 | 2009-03-15 | Advanced Renal Technologies | Anwendung eines dialysats mit hohem zitratgehalt |
DE19955578C1 (de) | 1999-11-18 | 2001-09-06 | Fresenius Medical Care De Gmbh | Mehrkammerbehälter, mit Glucosekonzentratkompartiment und Salzsäurekonzentratkompartiment |
JP3899506B2 (ja) | 2000-09-27 | 2007-03-28 | ニプロ株式会社 | 固形透析用製剤およびその製造方法 |
JP5204359B2 (ja) * | 2001-09-28 | 2013-06-05 | 味の素株式会社 | 透析用剤およびその製造方法 |
SE525132C2 (sv) | 2001-11-23 | 2004-12-07 | Gambro Lundia Ab | Metod vid manövrering av dialysanordning |
JP2003339853A (ja) * | 2002-05-27 | 2003-12-02 | Shimizu Pharmaceutical Co Ltd | 安定な透析用剤 |
US7238164B2 (en) | 2002-07-19 | 2007-07-03 | Baxter International Inc. | Systems, methods and apparatuses for pumping cassette-based therapies |
JP4647953B2 (ja) | 2003-12-26 | 2011-03-09 | マナック株式会社 | 一剤型重炭酸透析用固形剤及びその製造方法 |
WO2005074948A1 (ja) | 2004-02-09 | 2005-08-18 | Nipro Corporation | 透析用固形製剤およびその製造方法 |
WO2005094918A1 (ja) | 2004-03-30 | 2005-10-13 | Nipro Corporation | 透析用固形製剤 |
CA2570110A1 (en) | 2004-06-17 | 2006-01-19 | Gopal Iyengar | Multi-layer, high barrier packaging materials |
US7544301B2 (en) | 2004-08-19 | 2009-06-09 | Hhd Llc | Citrate-based dialysate chemical formulations |
CN101123987A (zh) * | 2005-01-07 | 2008-02-13 | 味之素株式会社 | 透析用制剂 |
RU2311202C1 (ru) | 2006-02-08 | 2007-11-27 | Общество С Ограниченной Ответственностью "Нпо "Нефрон" | Способ получения кислотного компонента для бикарбонатного гемодиализа |
JP5254043B2 (ja) * | 2006-02-22 | 2013-08-07 | ヘンリー フォード ヘルス システム | 体外血液回路への局所クエン酸塩抗凝血剤送達システム及び方法 |
US8133194B2 (en) * | 2006-02-22 | 2012-03-13 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
TWI440457B (zh) * | 2006-12-12 | 2014-06-11 | Ajinomoto Kk | 含檸檬酸及/或檸檬酸鹽之組成物的用途 |
CN101568334A (zh) * | 2006-12-12 | 2009-10-28 | 味之素株式会社 | 铁代谢改善剂 |
TWI419683B (zh) * | 2007-03-14 | 2013-12-21 | Ajinomoto Kk | 骨代謝改善劑 |
TWI516284B (zh) | 2007-05-31 | 2016-01-11 | 味之素股份有限公司 | 透析用固態製劑 |
WO2010055963A1 (en) | 2008-11-17 | 2010-05-20 | Lee, Jin Tae | Manufacturing method of acetate-free dialysate composition |
WO2010112570A1 (en) * | 2009-03-31 | 2010-10-07 | Gambro Lundia Ab | Dialysis solution |
WO2010112547A1 (en) | 2009-03-31 | 2010-10-07 | Gambro Lundia Ab | Dialysis precursor composition |
AU2011269109B2 (en) | 2010-06-23 | 2013-11-21 | Gambro Lundia Ab | Dialysis precursor composition |
US10993961B2 (en) | 2010-06-23 | 2021-05-04 | Gambro Lundia Ab | Dialysis precursor composition |
PL2720678T3 (pl) | 2011-06-20 | 2021-05-04 | Gambro Lundia Ab | Kompozycja prekursorowa do dializy |
ES2587862T3 (es) | 2011-06-20 | 2016-10-27 | Gambro Lundia Ab | Composición precursora de diálisis |
DE102011106248A1 (de) | 2011-07-01 | 2013-01-03 | Fresenius Medical Care Deutschland Gmbh | Behälter, Verwendung, Dialysegerät oder Zubereitungseinheit sowie Verfahren zur Herstellung eines Konzentrats |
-
2013
- 2013-03-15 AU AU2013201546A patent/AU2013201546B2/en active Active
- 2013-12-18 WO PCT/EP2013/077019 patent/WO2014095953A1/en active Application Filing
- 2013-12-18 CA CA2893478A patent/CA2893478C/en active Active
- 2013-12-18 EP EP13808025.4A patent/EP2934483B1/en active Active
- 2013-12-18 US US14/651,370 patent/US9925155B2/en active Active
- 2013-12-18 CN CN201380028249.7A patent/CN104349770A/zh active Pending
- 2013-12-18 CN CN201810454374.9A patent/CN108420790A/zh active Pending
- 2013-12-18 KR KR1020157019267A patent/KR102252944B1/ko active IP Right Grant
- 2013-12-18 JP JP2015548467A patent/JP6425661B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
AU2013201546A1 (en) | 2014-07-03 |
US20150313858A1 (en) | 2015-11-05 |
KR20150096753A (ko) | 2015-08-25 |
US9925155B2 (en) | 2018-03-27 |
WO2014095953A1 (en) | 2014-06-26 |
JP2016503768A (ja) | 2016-02-08 |
KR102252944B1 (ko) | 2021-05-18 |
AU2013201546B2 (en) | 2014-10-23 |
EP2934483B1 (en) | 2021-07-28 |
EP2934483A1 (en) | 2015-10-28 |
CA2893478A1 (en) | 2014-06-26 |
CN108420790A (zh) | 2018-08-21 |
CN104349770A (zh) | 2015-02-11 |
CA2893478C (en) | 2020-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI583378B (zh) | 透析酸前驅物組成物、其用途、以及提供透析酸濃縮物溶液之方法 | |
TWI500424B (zh) | 透析前驅物組成物 | |
KR102001689B1 (ko) | 투석 전구 조성물 | |
WO2010112570A1 (en) | Dialysis solution | |
KR20140145957A (ko) | 투석 전구 조성물 | |
WO2010112547A1 (en) | Dialysis precursor composition | |
JP6425661B2 (ja) | 透析組成物 | |
JPH07323084A (ja) | トレハロース含有腹膜透析液 | |
EP3452136B1 (en) | Dialysis concentrate | |
Chebrolu et al. | Phosphorus-enriched hemodialysis for the treatment of patients with severe methanol intoxication | |
JP5371278B2 (ja) | 透析用剤およびその製造方法 | |
KR101978010B1 (ko) | 투석 전구체 조성물 | |
KR101978011B1 (ko) | 투석 전구체 조성물 | |
KR100993178B1 (ko) | 구연산이 함유된 저농도 초산의 인공신장관류액 | |
TWI373339B (en) | Pharmaceutical composition for use in hemofiltration or hemodialysis | |
KR20180019069A (ko) | 시트르산염 및 글루코즈를 함유하는 산성 투석액 농축물을 위한 패키지 | |
WO2015009149A1 (en) | Calcium-free dialysis fluid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170801 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171101 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180125 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20180410 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20180412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180827 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181023 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6425661 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |